biopharmaceutical company Regeneron Pharmaceuticals, Inc. (REGN) posted a net profit for the fourth quarter of $470 million or $4.08 per share, compared to a net loss of $53 million or $0.58 per share in the year-ago quarter.
On a non-GAAP basis, profit was $171 million or $1.47 per share. On average, 15 analysts polled by Thomson Reuters expected the company to report earnings per share of $1.11 for the quarter. Analysts' estimates typically exclude one-time items.
For the quarter, the Company's total revenues surged to $415 million from $123 million in the last year. Total revenues included EYLEA U.S. net product sales of $276 million and collaboration revenues of $127 million in the fourth quarter
For 2013, the company said it expects continued strong U.S. growth for EYLEA and forecast U.S. net sales of $1.2 billion - $1.3 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.